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“Take Home” message: 
Beta-blockers (BB) are used for heart failure and after myocardial infarction but 
remain underused in COPD despite recommendations in guidelines.  
 
Prospective trials are needed to assess whether BB reduce exacerbations and 
deaths in COPD 
 
Abstract  
The combined effects on the heart of smoking and hypoxaemia may contribute to an 
increased cardiovascular burden in COPD. The use of beta-blockers in COPD has 
been proposed because of their known cardio-protective effects as well as reducing 
heart rate and improving systolic function. Despite the proven cardiac benefits of 
beta-blockers post myocardial infarction and in heart failure they remain underused 
due to concerns regarding potential bronchoconstriction even with cardio-selective 
drugs. Initiating treatment with beta-blockers requires dose titration and monitoring 
over a period of weeks, and beta-blockers may be less well tolerated in older 
patients with COPD who have other comorbidities. Medium term prospective placebo 
controlled safety studies in COPD are warranted to reassure prescribers regarding 
the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their 
potential interaction with concomitant inhaled long acting bronchodilator therapy. 
Several retrospective observational studies have shown impressive reductions in 
mortality and exacerbations conferred by beta-blockers in COPD. However, this 
requires confirmation from long term prospective placebo controlled randomized 
controlled trials. The real challenge is to establish whether beta-blockers confer 
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benefits on mortality and exacerbations in all patients with COPD including those 
with silent cardiovascular disease where the situation is less clear. 
  
Key words:  COPD, beta-blocker, coronary artery disease, heart failure, 
exacerbations 
 
Abstract word count: 198  
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Introduction  
Chronic obstructive pulmonary disease (COPD) is one of the world’s leading causes 
of morbidity and is now the third leading cause of mortality amounting to 3 million 
deaths in 2010.[1, 2] Exacerbations in particular account for up to three quarters of 
the total costs due to COPD,[3] with attributable costs exceeding 30 billion USD.[4] A 
recent COPD taskforce statement [5] identified an unmet need in terms of finding 
drugs to treat common co-morbidities specifically mentioning the putative effects of 
beta-blockers on the cardiovascular burden and its associated impact on mortality. 
Cardiovascular comorbidity is common in patients with COPD due to smoking in 
addition to other shared risks including genetic susceptibility, systemic inflammation 
and ageing.[6] The prevalence of COPD in patients with heart failure ranges from 11-
52% in North American patients and 9-41% in European patients.[7] The purpose of 
this article is to critically reappraise the current knowledge regarding beta-blockers in 
COPD looking at the current evidence for their therapeutic index and how this relates 
to management guidelines.  
We have not attempted a systematic review or meta-analysis as described 
elsewhere,[8-10] but rather highlighted the key areas of clinical relevance for 
physicians who treat patients with COPD. In this article we have 1) considered the 
putative link between COPD and the heart in terms of potential targets for beta-
blockers, 2) reviewed retrospective data linking use of beta-blockers to reduced 
exacerbations and mortality, 3) examined the unmet need for use of beta-blockers in 
patients with COPD and both known, and potentially unknown cardiovascular 
disease, 4) evaluated which beta-blocker to use based on their pharmacology and 
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impact on pulmonary function, and 5) attempted to draw conclusions about the 
current  clinical use of beta-blockers in COPD.   
 
 
COPD and the heart (Figure 1 and Box 1) 
The main accepted clinical indications for the use of beta-blockers in COPD are for 
patients post myocardial infarction and for patients with heart failure. However, the 
presence of untreated or unrecognized (i.e. silent) cardiovascular disease may 
contribute to mortality in COPD and may also be an underlying causative factor in 
exacerbations which can be difficult to separate from respiratory etiologies.[6] [7] It is 
also possible, if not likely, that the burden of cardiovascular disease may be under-
rated by pulmonologists when treating COPD patients because symptoms are 
presumed to be primarily driven by airflow obstruction, especially during 
exacerbations.  
The prevalence of left ventricular systolic dysfunction ranges between 10-46% in 
patients with COPD and though the occurrence of heart failure with preserved left 
ventricular ejection fraction is less clear, estimates in patients with severe COPD are 
as high as 90%.[7] The benefits of beta-blockers in patients with heart failure due to 
left ventricular systolic dysfunction are well established from pivotal trials as well as 
meta-analysis.[21-24]  The challenge in COPD may be more with respect to 
diagnosis of heart failure with echocardiography where image acquisition is difficult 
due to lung hyperinflation.[25]  
Beta-blockers only have proven benefits in patients post myocardial infarction but not 
in stable coronary arterial disease.[11, 12] Nevertheless, the presence of coronary 
calcium on chest CT scans is associated with  mortality in COPD,[13] and known 
coronary arterial disease is also associated with longer exacerbations, more 
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dyspnoea, lower health status and exercise capacity in stable patients with 
COPD.[14] There is also an acute increase in arterial stiffness particularly during 
infective exacerbations of COPD, along with increases in cardiac enzymes especially 
in patients with coronary arterial disease;[15] one study found that one in twelve 
patients admitted to hospital with an exacerbation of COPD met the criteria for a 
myocardial infarction.[16] The presence of coronary heart disease in COPD along 
with the adverse effects of hypoxaemia [17] may be compounded by the positive 
chronotropic effects of concomitant inhaled beta-agonist therapy,[18, 19] further 
compromising cardiac reserve. It has been shown that even a low dose of a beta-1 
selective antagonist such as atenolol might protect against chronotropic, inotropic 
and electrocardiographic effects of inhaled beta-agonists which are mediated by 
cardiac beta2 receptor stimulation.[20]  
Another potential target is diastolic dysfunction though a meta-analysis suggests that 
the beneficial effects of beta-blockers in such patients are less clear cut.[26]  Several 
factors may contribute to the occurrence of impaired diastolic function in COPD. 
Firstly, patients with COPD also appear to have a higher left ventricular mass 
(hypertrophy) even in the absence of left ventricular dilatation. Secondly, lung 
hyperinflation in COPD may cause cardiac compression reducing both left ventricular 
and atrial filling even in the absence of raised pulmonary arterial pressure.[28-30] 
These factors, may also be compounded by the negative  effects of hypoxaemia on 
diastolic filling.[31] [17]  
In addition to these COPD related risks, patients with the disease commonly have 
other co-morbidities such as coronary artery disease, hypertension and diabetes, 
which can all adversely affect diastolic function. This was addressed in a recent 
prospective longitudinal study of healthy young adults followed over 25 years, where 
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a fall in the ratio of forced expiratory volume in one second to forced vital capacity 
(FEV1/FVC) was associated with reduced left atrial size and cardiac output.[32] Left 
ventricular end diastolic and end systolic wall stress measured by magnetic 
resonance imaging (MRI) is associated with increasing severity of airflow obstruction 
in patients with COPD and coexistent heart failure.[33] Impaired left ventricular filling 
is clinically important because it can eventually produce left atrial enlargement which 
is a key risk factor for atrial fibrillation and associated mortality during exacerbations 
of COPD.[34] Furthermore, the presence of impaired diastolic filling in patients with 
COPD is also related to impaired walking distance.[35]  Thus, the absence of 
benefits of beta-blockers in diastolic dysfunction may not apply in COPD and 
deserved re-evaluation in this patient group. 
 
Effects of beta-blockers on mortality and exacerbations  
Due to the high cardiovascular comorbidity in COPD from smoking along with 
increased sympathetic drive due to hypoxaemia,[36] beta-blockers have been 
proposed as a cogent therapeutic intervention for their known cardio-protective 
effects in addition to reducing heart rate and improving systolic and diastolic 
dysfunction. One of the fundamental issues with regards to more widespread use of 
beta-blockers in COPD is the concern regarding beta2 receptor antagonism and 
associated airway smooth muscle constriction which may even occur with cardio-
selective agents which exhibit preferential beta1 blockade, especially in more 
susceptible severe patients with impaired respiratory reserve. The risk-benefit 
equation in COPD becomes more favorable for patients who already have overt 
cardiac disease such as heart failure or post myocardial infarction, where beta-
blockers have proven protective effects.[11, 21] There are, however, no data as to 
Page 7 of 63 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7 
 
 
the putative beneficial effects of beta-blockers in those the majority of COPD patients 
who may have concomitant silent coronary arterialheart disease or heart failure .  
Retrospective observational data have shown beneficial effects of beta-blockers in a 
cohort of 5977 patients with COPD who were followed over a mean of 4.35 years 
[37] where their use was associated with an overall 22% (95% confidence interval 8-
33) reduction in mortality. In a study b of 825 patients admitted to hospital for an 
exacerbation of COPD, beta-blocker use among 142 patients was associated with a 
61% (1-86) reduction in mortality.[38] Rutten et al showed 32% (17-44) and 29% (17-
40) reductions in mortality and exacerbations, respectively, conferred by taking beta-
blockers among 2230 patients with COPD followed up for a mean of 7.2 years.[39] In 
a cohort study from Sweden of 4858 patients with COPD, those who were 
discharged on a beta-blocker (84%) post myocardial infarction had 13% (2-22) lower 
mortality.[40] In a retrospective report of 256 patients with COPD with either 
coronary heart disease or heart failure, 58% were taking beta-blockers where there 
was a 73% (50-85) reduction in the likelihood of being admitted to a hospital 
emergency room.[41] In contrast, in an observational study using time dependent 
analysis of 2249 severe oxygen dependent COPD patients there was a 19% 
increase in mortality associated with taking beta-blockers.[42] However, in a 
prospectively followed cohort of 3464 patients Bhatt et al found a 27% (10-40) 
reduction in total exacerbations, while in GOLD 3/4 patients on home oxygen there 
was a 67% reduction (42-81).[43]    
In a 2012 meta-analysis of 9 retrospective cohort studies, the pooled estimate for 
mortality reduction with beta-blockers was reported to be 31% (22-38).[8] In a 
subsequent 2014 meta-analysis of 15 retrospective studies of 21,596 patients with 
COPD, the pooled estimate for reduction in overall mortality conferred by beta-
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blockers was 28% (17-37) and for exacerbations was 38% (18-58).[9] The reduction 
in mortality was 36% (24-46) among the subgroup of patients (5 studies: 39% 
weighting) with known coronary heart disease and 26% (7-42) in the subgroup with 
known heart failure (3 studies: 18% weighting).  
The beneficial effects of beta-blockers on exacerbations may involve other potential 
non-cardiac mechanisms whereby beta-blockers could reduce COPD exacerbations. 
In heart failure, use of cardioselective beta-blockers reduces systemic inflammatory 
cytokine release such as IL-6 and alters leukocyte distribution which may also impact 
inflammation during respiratory infections.[44] Beta-blockers have also been 
reported to inhibit neutrophil chemotaxis and oxygen free radical production,[45] 
while in human endothelial cells they have been reported to reduce the release of 
endothelin-1, a bronchoconstrictor peptide implicated in the pathogenesis of COPD 
exacerbations.[46, 47]   
It is not possible to eliminate the possibility of residual confounding in the 
observational studies suggesting beta-blockers may reduce exacerbations and 
mortality in COPD and thus definitive randomized trials are needed. There is now a 
planned placebo controlled trial powered for a reduction in exacerbations using 
metoprolol over 1 year via the US COPD Clinical Research Network and funded by 
the Department of Defense (Clinicaltrials.gov Identifier:NCT02587351). 
 
This study will only exclude those patients with an absolute indication for beta-
blockers including an MI or revascularization procedure within three years or with an 
ejection fraction <40%.  However, it remains possible that this and similar studies 
may run the risk of only including patients where beta-blockers are less efficacious. 
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The unmet cardiac need in COPD  
Beta-blockers have an established position in the management of coronary artery 
disease while heart failure guidelines reinforce their use in patients with concomitant 
COPD.[51] Similarly, COPD management strategies also state that the benefits of 
selective beta-1 blocker treatment in heart failure clearly outweigh any potential risk 
associated with treatment even in patients with severe COPD.[52] Despite this 
guidance there is a reluctance to prescribe even cardio-selective beta-blockers in 
COPD, even in the presence of known cardiac disease because of persistent 
concerns regarding potential bronchoconstriction, especially in more severe patients. 
In a cohort from Scotland we found that only 14% of patients with COPD were taking 
beta-blockers for cardiovascular comorbidity.[37] Further evidence of a reluctance to 
prescribe beta-blockers in COPD was documented by Quint et al where 55% of 
patients who had a myocardial infarction were not prescribed a beta-blocker, with 
only 22% being prescribed on admission.[53] In the UK 64% of patients without 
COPD and acute coronary syndrome were prescribed beta-blockers as compared to 
16% of similar patients with COPD who were prescribed beta-blockers.[54] 
Furthermore COPD was documented as a reason for withholding beta-blockers in 
33% of patients who did not receive a beta-blocker, while non-cardiologists were 
40% less likely to prescribe beta-blockers. In the United States, Chen et al found that 
elderly patients after an acute mycocardial infarction were 62% less likely to be given 
beta-blockers in the presence of a history of treated COPD or asthma.[55] Initiating 
treatment with beta-blockers is not simple as it requires dose titration over a period 
of weeks along with monitoring of heart rate, blood pressure and perhaps spirometry, 
all of which take time, incurring extra healthcare costs. Moreover beta-blockers may 
be less well tolerated in older patients with co-existing comorbidities such as 
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diabetes, peripheral vascular disease and renal impairment, who are more prone to 
postural hypotension. 
 
Choice of beta-blocker and effects on pulmonary function (Box 2) 
The mechanism of beta-blocker induced bronchoconstriction is thought to be due to 
the effects of pre and post-junctional beta2 receptor antagonism uncovering the 
prevailing cholinergic tone via post-junctional smooth muscle muscarinic type 3 
receptors, resulting in airway smooth muscle constriction.[57]   
In a subgroup analysis of 2712 patients from the Tayside cohort who had serial 
spirometry measures over 4 years, there was no deleterious effect of long term beta-
blocker use (88% were cardioselective) on either FEV1 or FVC, even among the 
more severe patients taking triple inhaled therapy, who had the greatest reductions 
in exacerbations and mortality.[37] In a meta-analysis of randomized controlled trials 
with cardio-selective beta-blockers there was no significant change in FEV1 
compared to placebo, when given either as single -2.1% (-6.1-2.0) or chronic dosing 
-2.6% (-5.9-0.8), and also no significantly effect on the FEV1 response to beta2-
agonists[10]. In a randomized controlled trial of 27 patients with heart failure who 
also had coexistent moderate to severe COPD, after 4 months of treatment there 
was a 190ml significant fall   FEV1 between bisoprolol and placebo, while salbutamol 
reversibility, symptoms and quality of life were unchanged.[60] In a comparison of 
bisoprolol and placebo in patients with moderate to severe COPD, there was a 
significantly worsening of dynamic hyperinflation during cycle endurance while 
exercise duration was unaltered.[61] In a study comparing 24 COPD patients on 
beta-blockers matched to patients not taking beta-blockers there was no difference 
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in exercise capacity  or gas exchange despite lower heart rate and blood pressure, in 
turn suggesting great oxygen delivery per heart beat.[62] 
The beta-blockers currently licensed for heart failure are the beta1 selective 
bisoprolol, nebivolol, metoprolol and the non-selective carvedilol. As has already 
been shown in heart failure [63] and asthma [49] it is important to slowly titrate up the 
dose of beta-blocker to improve cardiovascular and pulmonary tolerability. Bisoprolol 
has a licensed indication for use in heart failure and coronary artery disease and has 
a beta1/2 receptor selectivity ratio of 14:1, which is higher than either atenolol (5:1) or 
metoprolol (2:1).[64] In a cross-over study of 51 patients with COPD and heart 
failure, directly comparing 6 weeks of bisoprolol, metoprolol and carvedilol,[65] FEV1 
was lowest with carvedilol and highest with bisoprolol with metoprolol in between.  In 
a randomized controlled trial comparing bisoprolol (mean dose 6.4mg) and carvedilol 
(mean dose 47mg) in patients with heart failure and COPD, FEV1 significantly 
improved by 137ml with bisoprolol but not with carvedilol (30ml improvement).[66] In 
15 mild to moderate COPD patients there was a significant worsening in airway 
hyper-reactivity to methacholine challenge with metoprolol and propranolol but not 
celiprolol compared to placebo, while the acute bronchodilator response to fenoterol 
was only blunted by propranolol.[67] 
Nebivolol has been shown to exhibit greater in vitro beta1/2 receptor selectivity than 
bisoprolol in human myocardium.[68] In healthy volunteers attenuation of beta2 
receptor mediated terbutaline induced hypokalaemia was significantly greater with 
bisoprolol 10mg or atenolol 50mg/100mg verses nebivolol 5mg, which in turn was 
not different from placebo.[69] Nebivolol produced significant blunting of terbutaline 
induced glucose and insulin responses compared to placebo in keeping with beta2 
receptor antagonism at the 5mg dose. However the relative beta1/2 selectivity cannot 
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be inferred since this would require comparison of beta-blocker doses which exhibit 
the same degree of beta1 antagonism as assessed by exercise heart rate 
reduction,[70] which was not measured.  
In a post hoc analysis of 2670 patients from the organized program to initiate 
lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF), there 
were no differences between selective and non-selective beta-blockers in terms of 
lower mortality or re-hospitalization in patients with and without COPD.[72]  
Carvedilol blocks both cardiac beta1 and beta2 receptors as well as exhibiting 
peripheral vasodilatation due to alpha receptor blockade, which in addition to its anti-
oxidant activity [73] may explain its superiority verses metoprolol in heart failure in 
one particular study, which may not have compared comparable doses.[63] Until 
there is more convincing evidence to support the superiority of carvedilol in heart 
failure, it would be prudent to choose a selective agent such as bisoprolol, nebivolol 
or metoprolol due to their superior safety profile in COPD.  
Long acting muscarinic antagonists such as tiotropium have been shown to obviate 
bronchoconstriction even when using non-selective beta-blockade with propranolol in 
asthmatic patients.[58]  It is the more severe COPD patients who would in theory be 
most at risk of beta-blocker induced bronchoconstriction. These patients would 
usually already be taking concomitant LAMA and hence be protected from 
bronchospasm. The relatively small degree of dose related beta2 receptor 
antagonism conferred for example by bisoprolol [59] would not be expected  to result 
in worsening of pulmonary function. It is also important to consider the potential 
impact of beta2 receptor genotype on the risk-benefit equation with beta-blockers in 
COPD. It has been shown that asthmatic patients who possess one or two copies of 
the arginine-16 beta2 receptor polymorphism are more prone to propranolol induced 
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bronchoconstriction in terms of FEV1 and airway resistance.[75] While the arginine-
16 polymorphism conferred a worse outcome on survival in patients receiving 
metoprolol after an acute coronary syndrome,[76] it was not associated with survival 
in HF patients treated with metoprolol or carvedilol.[77] 
 
Conclusions and the ways forward (Box 3) 
There are compelling reasons to use cardio-selective beta-blockers in patients with 
COPD who have coexistent heart failure or are post myocardial infarction. Current 
evidence would suggest that there remains a reticence to prescribe beta-blockers in 
such patients because of a fear of adverse events, particularly worsened lung 
function. Further prospective medium term safety studies are therefore required to 
carefully follow effects of cardio-selective drugs on pulmonary function in patients 
with more severe COPD by employing slow initial dose titration as well as evaluating 
their interaction with long acting bronchodilators (ClinicalTrials.gov 
Identifier:NCT01656005).  
There is currently not sufficient evidence to advocate treatment with beta-blockers 
for the prevention of exacerbations or exacerbation-related mortality. Long term 
placebo controlled multicenter trials in COPD are indicated to confirm the benefits of 
beta-blockers already seen on mortality and exacerbations in observational studies. 
The key question to answer is whether the potential benefits of beta-blockers are 
confined to those patients with known cardiovascular disease or are present in the 
wider population who may have silent cardiovascular disease.  Likewise, beta-
blockers are not currently indicated in COPD patients with diastolic dysfunction alone 
where controlled trials are also warranted. 
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Beta-blockers are likely to be part of a more complex therapeutic jigsaw in 
addressing the composite risk from different cardiovascular abnormalities in COPD, 
and as has already been shown with heart failure there may be additive effects from 
drugs acting on other neuro-hormonal pathways. This includes drugs which block the 
renin-angiotensin system that may be particularly effective at regressing left 
ventricular hypertrophy.[78] Dual angiotensin/neprolysin inhibition [79] may also 
confer benefits by augmenting BNP levels and ameliorate the adverse effects of 
hypoxic pulmonary vasoconstriction.[80, 81] Anti-platelet drugs might also be 
beneficial for treating silent coronary artery disease in more severe COPD patients 
who are oxygen dependent.[42] Pulmonologists have tended to focus on drugs 
which act on the lung rather than the heart, because of the evidence supporting the 
former.  Perhaps now is time to look at the lungs’ next door neighbour in the chest 
and begin to address the unmet need of cardiac disease in COPD.  
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“Take Home” message: 
Beta-blockers (BB) are used for heart failure and after myocardial infarction but 
remain underused in COPD despite recommendations in guidelines.  
 
Abstract  
The combined effects on the heart of smoking and hypoxaemia may contribute to an 
increased cardiovascular burden in COPD. The use of beta-blockers in COPD has 
been proposed because of their known cardio-protective effects as well as reducing 
heart rate and improving systolic function. Despite the proven cardiac benefits of 
beta-blockers post myocardial infarction and in heart failure they remain underused 
due to concerns regarding potential bronchoconstriction even with cardio-selective 
drugs. Initiating treatment with beta-blockers requires dose titration and monitoring 
over a period of weeks, and beta-blockers may be less well tolerated in older 
patients with COPD who have other comorbidities. Medium term prospective placebo 
controlled safety studies in COPD are warranted to reassure prescribers regarding 
the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their 
potential interaction with concomitant inhaled long acting bronchodilator therapy. 
Several retrospective observational studies have shown impressive reductions in 
mortality and exacerbations conferred by beta-blockers in COPD. However, this 
requires confirmation from long term prospective placebo controlled randomized 
controlled trials. The real challenge is to establish whether beta-blockers confer 
benefits on mortality and exacerbations in all patients with COPD including those 
with silent cardiovascular disease where the situation is less clear. 
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Introduction  
Chronic obstructive pulmonary disease (COPD) is one of the world’s leading causes 
of morbidity and is now the third leading cause of mortality amounting to 3 million 
deaths in 2010.[1, 2] Exacerbations in particular account for up to three quarters of 
the total costs due to COPD,[3] with attributable costs exceeding 30 billion USD.[4] A 
recent COPD taskforce statement [5] identified an unmet need in terms of finding 
drugs to treat common co-morbidities specifically mentioning the putative effects of 
beta-blockers on the cardiovascular burden and its associated impact on mortality. 
Cardiovascular comorbidity is common in patients with COPD due to smoking in 
addition to other shared risks including genetic susceptibility, systemic inflammation 
and ageing.[6] The prevalence of COPD in patients with heart failure ranges from 11-
52% in North American patients and 9-41% in European patients.[7] The purpose of 
this article is to critically reappraise the current knowledge regarding beta-blockers in 
COPD looking at the current evidence for their therapeutic index and how this relates 
to management guidelines.  
We have not attempted a systematic review or meta-analysis as described 
elsewhere,[8-10] but rather highlighted the key areas of clinical relevance for 
physicians who treat patients with COPD. In this article we have 1) considered the 
putative link between COPD and the heart in terms of potential targets for beta-
blockers, 2) reviewed retrospective data linking use of beta-blockers to reduced 
exacerbations and mortality, 3) examined the unmet need for use of beta-blockers in 
patients with COPD and both known, and potentially unknown cardiovascular 
disease, 4) evaluated which beta-blocker to use based on their pharmacology and 
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impact on pulmonary function, and 5) attempted to draw conclusions about the 
current  clinical use of beta-blockers in COPD.   
 
 
COPD and the heart (Figure 1 and Box 1) 
The main accepted clinical indications for the use of beta-blockers in COPD are for 
patients post myocardial infarction and for patients with heart failure. However, the 
presence of untreated or unrecognized (i.e. silent) cardiovascular disease may 
contribute to mortality in COPD and may also be an underlying causative factor in 
exacerbations which can be difficult to separate from respiratory etiologies.[6] [7] It is 
also possible, if not likely, that the burden of cardiovascular disease may be under-
rated by pulmonologists when treating COPD patients because symptoms are 
presumed to be primarily driven by airflow obstruction, especially during 
exacerbations.  
The prevalence of left ventricular systolic dysfunction ranges between 10-46% in 
patients with COPD and though the occurrence of heart failure with preserved left 
ventricular ejection fraction is less clear, estimates in patients with severe COPD are 
as high as 90%.[7] The benefits of beta-blockers in patients with heart failure due to 
left ventricular systolic dysfunction are well established from pivotal trials as well as 
meta-analysis.[21-24]  The challenge in COPD may be more with respect to 
diagnosis of heart failure with echocardiography where image acquisition is difficult 
due to lung hyperinflation.[25]  
Beta-blockers only have proven benefits in patients post myocardial infarction but not 
in stable coronary arterial disease.[11, 12] Nevertheless, the presence of coronary 
calcium on chest CT scans is associated with  mortality in COPD,[13] and known 
coronary arterial disease is also associated with longer exacerbations, more 
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dyspnoea, lower health status and exercise capacity in stable patients with 
COPD.[14] There is also an acute increase in arterial stiffness particularly during 
infective exacerbations of COPD, along with increases in cardiac enzymes especially 
in patients with coronary arterial disease;[15] one study found that one in twelve 
patients admitted to hospital with an exacerbation of COPD met the criteria for a 
myocardial infarction.[16] The presence of coronary heart disease in COPD along 
with the adverse effects of hypoxaemia [17] may be compounded by the positive 
chronotropic effects of concomitant inhaled beta-agonist therapy,[18, 19] further 
compromising cardiac reserve. It has been shown that even a low dose of a beta-1 
selective antagonist such as atenolol might protect against chronotropic, inotropic 
and electrocardiographic effects of inhaled beta-agonists which are mediated by 
cardiac beta2 receptor stimulation.[20]  
Another potential target is diastolic dysfunction though a meta-analysis suggests that 
the beneficial effects of beta-blockers in such patients are less clear cut.[26]  Several 
factors may contribute to the occurrence of impaired diastolic function in COPD. 
Firstly, patients with COPD also appear to have a higher left ventricular mass 
(hypertrophy) even in the absence of left ventricular dilatation. Secondly, lung 
hyperinflation in COPD may cause cardiac compression reducing both left ventricular 
and atrial filling even in the absence of raised pulmonary arterial pressure.[28-30] 
These factors, may also be compounded by the negative  effects of hypoxaemia on 
diastolic filling.[31] [17]  
In addition to these COPD related risks, patients with the disease commonly have 
other co-morbidities such as coronary artery disease, hypertension and diabetes, 
which can all adversely affect diastolic function. This was addressed in a recent 
prospective longitudinal study of healthy young adults followed over 25 years, where 
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a fall in the ratio of forced expiratory volume in one second to forced vital capacity 
(FEV1/FVC) was associated with reduced left atrial size and cardiac output.[32] Left 
ventricular end diastolic and end systolic wall stress measured by magnetic 
resonance imaging (MRI) is associated with increasing severity of airflow obstruction 
in patients with COPD and coexistent heart failure.[33] Impaired left ventricular filling 
is clinically important because it can eventually produce left atrial enlargement which 
is a key risk factor for atrial fibrillation and associated mortality during exacerbations 
of COPD.[34] Furthermore, the presence of impaired diastolic filling in patients with 
COPD is also related to impaired walking distance.[35]  Thus, the absence of 
benefits of beta-blockers in diastolic dysfunction may not apply in COPD and 
deserved re-evaluation in this patient group. 
 
Effects of beta-blockers on mortality and exacerbations  
Due to the high cardiovascular comorbidity in COPD from smoking along with 
increased sympathetic drive due to hypoxaemia,[36] beta-blockers have been 
proposed as a cogent therapeutic intervention for their known cardio-protective 
effects in addition to reducing heart rate and improving systolic and diastolic 
dysfunction. One of the fundamental issues with regards to more widespread use of 
beta-blockers in COPD is the concern regarding beta2 receptor antagonism and 
associated airway smooth muscle constriction which may even occur with cardio-
selective agents which exhibit preferential beta1 blockade, especially in more 
susceptible severe patients with impaired respiratory reserve. The risk-benefit 
equation in COPD becomes more favorable for patients who already have overt 
cardiac disease such as heart failure or post myocardial infarction, where beta-
blockers have proven protective effects.[11, 21] There are, however, no data as to 
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the putative beneficial effects of beta-blockers in those COPD patients who may 
have concomitant silent coronary arterial disease or heart failure.  
Retrospective observational data have shown beneficial effects of beta-blockers in a 
cohort of 5977 patients with COPD who were followed over a mean of 4.35 years 
[37] where their use was associated with an overall 22% (95% confidence interval 8-
33) reduction in mortality. In a study b of 825 patients admitted to hospital for an 
exacerbation of COPD, beta-blocker use among 142 patients was associated with a 
61% (1-86) reduction in mortality.[38] Rutten et al showed 32% (17-44) and 29% (17-
40) reductions in mortality and exacerbations, respectively, conferred by taking beta-
blockers among 2230 patients with COPD followed up for a mean of 7.2 years.[39] In 
a cohort study from Sweden of 4858 patients with COPD, those who were 
discharged on a beta-blocker (84%) post myocardial infarction had 13% (2-22) lower 
mortality.[40] In a retrospective report of 256 patients with COPD with either 
coronary heart disease or heart failure, 58% were taking beta-blockers where there 
was a 73% (50-85) reduction in the likelihood of being admitted to a hospital 
emergency room.[41] In contrast, in an observational study using time dependent 
analysis of 2249 severe oxygen dependent COPD patients there was a 19% 
increase in mortality associated with taking beta-blockers.[42] However, in a 
prospectively followed cohort of 3464 patients Bhatt et al found a 27% (10-40) 
reduction in total exacerbations, while in GOLD 3/4 patients on home oxygen there 
was a 67% reduction (42-81).[43]    
In a 2012 meta-analysis of 9 retrospective cohort studies, the pooled estimate for 
mortality reduction with beta-blockers was reported to be 31% (22-38).[8] In a 
subsequent 2014 meta-analysis of 15 retrospective studies of 21,596 patients with 
COPD, the pooled estimate for reduction in overall mortality conferred by beta-
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blockers was 28% (17-37) and for exacerbations was 38% (18-58).[9] The reduction 
in mortality was 36% (24-46) among the subgroup of patients (5 studies: 39% 
weighting) with known coronary heart disease and 26% (7-42) in the subgroup with 
known heart failure (3 studies: 18% weighting).  
The beneficial effects of beta-blockers on exacerbations may involve other potential 
non-cardiac mechanisms whereby beta-blockers could reduce COPD exacerbations. 
In heart failure, use of cardioselective beta-blockers reduces systemic inflammatory 
cytokine release such as IL-6 and alters leukocyte distribution which may also impact 
inflammation during respiratory infections.[44] Beta-blockers have also been 
reported to inhibit neutrophil chemotaxis and oxygen free radical production,[45] 
while in human endothelial cells they have been reported to reduce the release of 
endothelin-1, a bronchoconstrictor peptide implicated in the pathogenesis of COPD 
exacerbations.[46, 47]   
It is not possible to eliminate the possibility of residual confounding in the 
observational studies suggesting beta-blockers may reduce exacerbations and 
mortality in COPD and thus definitive randomized trials are needed. There is now a 
planned placebo controlled trial powered for a reduction in exacerbations using 
metoprolol over 1 year via the US COPD Clinical Research Network and funded by 
the Department of Defense (Clinicaltrials.gov Identifier:NCT02587351). 
 
This study will only exclude those patients with an absolute indication for beta-
blockers including an MI or revascularization procedure within three years or with an 
ejection fraction <40%.  However, it remains possible that this and similar studies 
may run the risk of only including patients where beta-blockers are less efficacious. 
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The unmet cardiac need in COPD  
Beta-blockers have an established position in the management of coronary artery 
disease while heart failure guidelines reinforce their use in patients with concomitant 
COPD.[51] Similarly, COPD management strategies also state that the benefits of 
selective beta-1 blocker treatment in heart failure clearly outweigh any potential risk 
associated with treatment even in patients with severe COPD.[52] Despite this 
guidance there is a reluctance to prescribe even cardio-selective beta-blockers in 
COPD, even in the presence of known cardiac disease because of persistent 
concerns regarding potential bronchoconstriction, especially in more severe patients. 
In a cohort from Scotland we found that only 14% of patients with COPD were taking 
beta-blockers for cardiovascular comorbidity.[37] Further evidence of a reluctance to 
prescribe beta-blockers in COPD was documented by Quint et al where 55% of 
patients who had a myocardial infarction were not prescribed a beta-blocker, with 
only 22% being prescribed on admission.[53] In the UK 64% of patients without 
COPD and acute coronary syndrome were prescribed beta-blockers as compared to 
16% of similar patients with COPD who were prescribed beta-blockers.[54] 
Furthermore COPD was documented as a reason for withholding beta-blockers in 
33% of patients who did not receive a beta-blocker, while non-cardiologists were 
40% less likely to prescribe beta-blockers. In the United States, Chen et al found that 
elderly patients after an acute mycocardial infarction were 62% less likely to be given 
beta-blockers in the presence of a history of treated COPD or asthma.[55] Initiating 
treatment with beta-blockers is not simple as it requires dose titration over a period 
of weeks along with monitoring of heart rate, blood pressure and perhaps spirometry, 
all of which take time, incurring extra healthcare costs. Moreover beta-blockers may 
be less well tolerated in older patients with co-existing comorbidities such as 
Page 39 of 63 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10 
 
 
diabetes, peripheral vascular disease and renal impairment, who are more prone to 
postural hypotension. 
 
Choice of beta-blocker and effects on pulmonary function (Box 2) 
The mechanism of beta-blocker induced bronchoconstriction is thought to be due to 
the effects of pre and post-junctional beta2 receptor antagonism uncovering the 
prevailing cholinergic tone via post-junctional smooth muscle muscarinic type 3 
receptors, resulting in airway smooth muscle constriction.[57]   
In a subgroup analysis of 2712 patients from the Tayside cohort who had serial 
spirometry measures over 4 years, there was no deleterious effect of long term beta-
blocker use (88% were cardioselective) on either FEV1 or FVC, even among the 
more severe patients taking triple inhaled therapy, who had the greatest reductions 
in exacerbations and mortality.[37] In a meta-analysis of randomized controlled trials 
with cardio-selective beta-blockers there was no significant change in FEV1 
compared to placebo, when given either as single -2.1% (-6.1-2.0) or chronic dosing 
-2.6% (-5.9-0.8), and also no significantly effect on the FEV1 response to beta2-
agonists[10]. In a randomized controlled trial of 27 patients with heart failure who 
also had coexistent moderate to severe COPD, after 4 months of treatment there 
was a 190ml significant fall   FEV1 between bisoprolol and placebo, while salbutamol 
reversibility, symptoms and quality of life were unchanged.[60] In a comparison of 
bisoprolol and placebo in patients with moderate to severe COPD, there was a 
significantly worsening of dynamic hyperinflation during cycle endurance while 
exercise duration was unaltered.[61] In a study comparing 24 COPD patients on 
beta-blockers matched to patients not taking beta-blockers there was no difference 
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in exercise capacity  or gas exchange despite lower heart rate and blood pressure, in 
turn suggesting great oxygen delivery per heart beat.[62] 
The beta-blockers currently licensed for heart failure are the beta1 selective 
bisoprolol, nebivolol, metoprolol and the non-selective carvedilol. As has already 
been shown in heart failure [63] and asthma [49] it is important to slowly titrate up the 
dose of beta-blocker to improve cardiovascular and pulmonary tolerability. Bisoprolol 
has a licensed indication for use in heart failure and coronary artery disease and has 
a beta1/2 receptor selectivity ratio of 14:1, which is higher than either atenolol (5:1) or 
metoprolol (2:1).[64] In a cross-over study of 51 patients with COPD and heart 
failure, directly comparing 6 weeks of bisoprolol, metoprolol and carvedilol,[65] FEV1 
was lowest with carvedilol and highest with bisoprolol with metoprolol in between.  In 
a randomized controlled trial comparing bisoprolol (mean dose 6.4mg) and carvedilol 
(mean dose 47mg) in patients with heart failure and COPD, FEV1 significantly 
improved by 137ml with bisoprolol but not with carvedilol (30ml improvement).[66] In 
15 mild to moderate COPD patients there was a significant worsening in airway 
hyper-reactivity to methacholine challenge with metoprolol and propranolol but not 
celiprolol compared to placebo, while the acute bronchodilator response to fenoterol 
was only blunted by propranolol.[67] 
Nebivolol has been shown to exhibit greater in vitro beta1/2 receptor selectivity than 
bisoprolol in human myocardium.[68] In healthy volunteers attenuation of beta2 
receptor mediated terbutaline induced hypokalaemia was significantly greater with 
bisoprolol 10mg or atenolol 50mg/100mg verses nebivolol 5mg, which in turn was 
not different from placebo.[69] Nebivolol produced significant blunting of terbutaline 
induced glucose and insulin responses compared to placebo in keeping with beta2 
receptor antagonism at the 5mg dose. However the relative beta1/2 selectivity cannot 
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be inferred since this would require comparison of beta-blocker doses which exhibit 
the same degree of beta1 antagonism as assessed by exercise heart rate 
reduction,[70] which was not measured.  
In a post hoc analysis of 2670 patients from the organized program to initiate 
lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF), there 
were no differences between selective and non-selective beta-blockers in terms of 
lower mortality or re-hospitalization in patients with and without COPD.[72]  
Carvedilol blocks both cardiac beta1 and beta2 receptors as well as exhibiting 
peripheral vasodilatation due to alpha receptor blockade, which in addition to its anti-
oxidant activity [73] may explain its superiority verses metoprolol in heart failure in 
one particular study, which may not have compared comparable doses.[63] Until 
there is more convincing evidence to support the superiority of carvedilol in heart 
failure, it would be prudent to choose a selective agent such as bisoprolol, nebivolol 
or metoprolol due to their superior safety profile in COPD.  
Long acting muscarinic antagonists such as tiotropium have been shown to obviate 
bronchoconstriction even when using non-selective beta-blockade with propranolol in 
asthmatic patients.[58]  It is the more severe COPD patients who would in theory be 
most at risk of beta-blocker induced bronchoconstriction. These patients would 
usually already be taking concomitant LAMA and hence be protected from 
bronchospasm. The relatively small degree of dose related beta2 receptor 
antagonism conferred for example by bisoprolol [59] would not be expected  to result 
in worsening of pulmonary function. It is also important to consider the potential 
impact of beta2 receptor genotype on the risk-benefit equation with beta-blockers in 
COPD. It has been shown that asthmatic patients who possess one or two copies of 
the arginine-16 beta2 receptor polymorphism are more prone to propranolol induced 
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bronchoconstriction in terms of FEV1 and airway resistance.[75] While the arginine-
16 polymorphism conferred a worse outcome on survival in patients receiving 
metoprolol after an acute coronary syndrome,[76] it was not associated with survival 
in HF patients treated with metoprolol or carvedilol.[77] 
 
Conclusions and the ways forward (Box 3) 
There are compelling reasons to use cardio-selective beta-blockers in patients with 
COPD who have coexistent heart failure or are post myocardial infarction. Current 
evidence would suggest that there remains a reticence to prescribe beta-blockers in 
such patients because of a fear of adverse events, particularly worsened lung 
function. Further prospective medium term safety studies are therefore required to 
carefully follow effects of cardio-selective drugs on pulmonary function in patients 
with more severe COPD by employing slow initial dose titration as well as evaluating 
their interaction with long acting bronchodilators (ClinicalTrials.gov 
Identifier:NCT01656005).  
There is currently not sufficient evidence to advocate treatment with beta-blockers 
for the prevention of exacerbations or exacerbation-related mortality. Long term 
placebo controlled multicenter trials in COPD are indicated to confirm the benefits of 
beta-blockers already seen on mortality and exacerbations in observational studies. 
The key question to answer is whether the potential benefits of beta-blockers are 
confined to those patients with known cardiovascular disease or are present in the 
wider population who may have silent cardiovascular disease.  Likewise, beta-
blockers are not currently indicated in COPD patients with diastolic dysfunction alone 
where controlled trials are also warranted. 
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Beta-blockers are likely to be part of a more complex therapeutic jigsaw in 
addressing the composite risk from different cardiovascular abnormalities in COPD, 
and as has already been shown with heart failure there may be additive effects from 
drugs acting on other neuro-hormonal pathways. This includes drugs which block the 
renin-angiotensin system that may be particularly effective at regressing left 
ventricular hypertrophy.[78] Dual angiotensin/neprolysin inhibition [79] may also 
confer benefits by augmenting BNP levels and ameliorate the adverse effects of 
hypoxic pulmonary vasoconstriction.[80, 81] Anti-platelet drugs might also be 
beneficial for treating silent coronary artery disease in more severe COPD patients 
who are oxygen dependent.[42] Pulmonologists have tended to focus on drugs 
which act on the lung rather than the heart, because of the evidence supporting the 
former.  Perhaps now is time to look at the lungs’ next door neighbour in the chest 
and begin to address the unmet need of cardiac disease in COPD.  
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Potential cardiac targets for beta-blockers in COPD (Box 1) 
 
• Improved left ventricular systolic and diastolic function  
• Reduced left ventricular dilatation   
• Protection against myocardial ischemia 
• Reduced left ventricular mass  
• Reduced heart rate  
• Anti-arrhythmic effects 
• Inhibition  of myocyte apoptosis  
• Protection against hypoxic sympathetic drive 
• Protection against adverse effects of beta-agonists  
 
Potential non-cardiac targets for beta-blockers in COPD 
 
• Inhibition of endothelin-1 release 
• Reduction in circulating pro-inflammatory cytokines 
• Inhibition of neutrophil chemotaxis and respiratory burst 
• Reduction in Goblet cell number and mucus release 
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Prescribing of beta-blockers in COPD for cardiovascular disease (Box 2) 
 
• Beta-1 selective antagonists including metoprolol, bisoprolol and 
nebivolol exhibit dose related beta-2 receptor blockade 
• Carvedilol is a non-selective beta-antagonist which is more likely to 
cause bronchoconstriction than beta-1 selective antagonists 
• Slowly titrate the dose of beta-blockers at 1-2 weekly intervals up to the 
usual maintenance dose  
• Monitor supine and erect blood pressure, heart rate and spirometry 
during dose titration  
• Concomitant long-acting muscarinic antagonists may obviate potential 
bronchoconstriction  
• Symptomatic bradycardia may occur if beta-blockers are used with 
other rate limiting drugs such as calcium blockers (e.g. verapamil, 
diltiazem), ivabradine or anti-arrhythmic agents (e.g. digoxin, 
amiodarone, flecainide) 
• Symptomatic hypotension may occur when beta-blockers are used with 
other vasodilator drugs (e.g. angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, calcium channel blockers, alpha 
receptor blockers) 
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Key messages (Box 3) 
 
• Cardiovascular comorbidity, including coronary artery disease and 
heart failure, commonly coexists in COPD due to the effects of 
smoking, systemic inflammation, hypoxaemia and other shared risks. 
• COPD may also be associated with impaired diastolic filling due to lung 
hyperinflation, which may be compounded by the negative lusitropic 
effects of hypoxaemia and left ventricular hypertrophy. 
• The main indications for beta blockers in patients with COPD are post 
myocardial infarction and heart failure with reduced ejection fraction. 
Despite clear evidence beta-blockers improve outcomes in these 
COPD patients they remain significantly underused due to concerns 
about adverse respiratory effects, even with beta-1 selective 
antagonists. 
• Meta-analyses of retrospective studies with beta-blockers in COPD 
have shown pooled estimates for reductions in mortality of 28% and 
exacerbations of 38%. 
• Initiating treatment with beta-blockers requires careful dose titration 
and monitoring.  This may be particularly relevant for patients with 
COPD who are often older and have other comorbidities that increase 
the risk of intolerance.  
• Beta-1 selective antagonists such as bisoprolol, nebivolol and 
metoprolol are preferred to the non-selective carvedilol as they are less 
likely to produce bronchoconstriction in COPD. 
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• Long acting muscarinic antagonists, which are commonly used in 
COPD protect against the potential for bronchoconstriction due to dose 
related beta-2 receptor antagonism. 
• The key unanswered question is whether beta-blockers may confer 
benefits on mortality and exacerbations in all patients with COPD 
including those with silent cardiovascular disease. 
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LA 
LV 
RV 
RA LVH  
Hypoxic sympathetic drive  
Extrinsic cardiac 
compression  
CAD   
LV ↓  
 β-agonists 
LA ⬆  
Systemic 
Inflammation 
Cardio-pulmonary interactions in COPD  
LA↑ left atrial dilatation , LV ↓ : reduced LV filling  LVH: left ventricular hypertrophy 
CAD: coronary artery disease, PoHT: pulmonary hypertension , RV ↓:reduced right ventricular filling  
RVH: right ventricular hypertrophy  
 
Cardiac 
Arrhythmias  
PoHT  
RVH/ RV ↓ 
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